Seminars in Perinatology
Volume 31, Issue 3 , Pages 126-134 , June 2007

Fetal Growth Restriction and Subsequent Pregnancy Risks

  • Wendy L. Kinzler, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Wendy L. Kinzler, MD, Department of Obstetrics, Gynecology and Reproductive Sciences, Clinical Academic Building, 2nd Floor, 125 Paterson Street, New Brunswick, NJ 08901.
    • ,
  • Lillian Kaminsky, MD

References 

  1. Snijders RJ, Sherrod C, Gosden CM, et al. Fetal growth retardation: associated malformations and chromosomal abnormalities. Am J Obstet Gynecol. 1993;168:547–555
  2. Creasy RLR. Maternal–Fetal Medicine. Philadelphia, PA: Saunders; 2005;
  3. Khoury MJ, Erickson JD, Cordero JF, et al. Congenital malformations and intrauterine growth retardation: a population study. Pediatrics. 1988;82:83–90
  4. Hannula K, Lipsanen-Nyman M, Kristo P, et al. Genetic screening for maternal uniparental disomy of chromosome 7 in prenatal and postnatal growth retardation of unknown cause. Pediatrics. 2002;109:441–448
  5. Kotzot D, Lurie IW, Mehes K, et al. No evidence of uniparental disomy 2, 6, 14, 16, 20, and 22 as a major cause of intrauterine growth retardation. Clin Genet. 2000;58:177–180
  6. Brown ZA, Vontver LA, Benedetti J, et al. Effects on infants of a first episode of genital herpes during pregnancy. N Engl J Med. 1987;317:1246–1251
  7. Meyberg-Solomayer GC, Fehm T, Muller-Hansen I, et al. Prenatal ultrasound diagnosis, follow-up, and outcome of congenital varicella syndrome. Fetal Diagn Ther. 2006;21:296–301
  8. Donner C, Liesnard C, Content J, et al. Prenatal diagnosis of 52 pregnancies at risk for congenital cytomegalovirus infection. Obstet Gynecol. 1993;82:481–486
  9. Daffos F, Forestier F, Capella-Pavlovsky M, et al. Prenatal management of 746 pregnancies at risk for congenital toxoplasmosis. N Engl J Med. 1988;318:271–275
  10. Khan NA, Kazzi SN. Yield and costs of screening growth-retarded infants for torch infections. Am J Perinatol. 2000;17:131–135
  11. Arbuckle TE, Wilkins R, Sherman GJ. Birth weight percentiles by gestational age in Canada. Obstet Gynecol. 1993;81:39–48
  12. Houlton MC, Marivate M, Philpott RH. The prediction of fetal growth retardation in twin pregnancy. Br J Obstet Gynaecol. 1981;88:264–273
  13. Secher NJ, Kaern J, Hansen PK. Intrauterine growth in twin pregnancies: prediction of fetal growth retardation. Obstet Gynecol. 1985;66:63–68
  14. Sherer DM, Divon MY. Fetal growth in multifetal gestation. Clin Obstet Gynecol. 1997;40:764–770
  15. Bjoro K. Vascular anomalies of the umbilical cord (I. Obstetric implications). Early Hum Dev. 1983;8:119–127
  16. Predanic M, Perni SC, Friedman A, et al. Fetal growth assessment and neonatal birth weight in fetuses with an isolated single umbilical artery. Obstet Gynecol. 2005;105:1093–1097
  17. Heinonen S, Ryynanen M, Kirkinen P, et al. Perinatal diagnostic evaluation of velamentous umbilical cord insertion: clinical, Doppler, and ultrasonic findings. Obstet Gynecol. 1996;87:112–117
  18. Rolschau J. Circumvallate placenta and intrauterine growth retardation. Acta Obstet Gynecol Scand Suppl. 1978;72:11–14
  19. Nagy S, Bush M, Stone J, et al. Clinical significance of subchorionic and retroplacental hematomas detected in the first trimester of pregnancy. Obstet Gynecol. 2003;102:94–100
  20. Ananth CV, Berkowitz GS, Savitz DA, et al. Placental abruption and adverse perinatal outcomes. J Am Med Assoc. 1999;282:1646–1651
  21. Sheiner E, Shoham-Vardi I, Hallak M, et al. Placental abruption in term pregnancies: clinical significance and obstetric risk factors. J Matern Fetal Neonatal Med. 2003;13:45–49
  22. Ananth CV, Demissie K, Smulian JC, et al. Relationship among placenta previa, fetal growth restriction, and preterm delivery: a population-based study. Obstet Gynecol. 2001;98:299–306
  23. Laurini R, Laurin J, Marsal K. Placental histology and fetal blood flow in intrauterine growth retardation. Acta Obstet Gynecol Scand. 1994;73:529–534
  24. Salafia CM, Vintzileos AM, Silberman L, et al. Placental pathology of idiopathic intrauterine growth retardation at term. Am J Perinatol. 1992;9:179–184
  25. Bane AL, Gillan JE. Massive perivillous fibrinoid causing recurrent placental failure. Br J Obstet Gynaecol. 2003;110:292–295
  26. Mandsager NT, Bendon R, Mostello D, et al. Maternal floor infarction of the placenta: prenatal diagnosis and clinical significance. Obstet Gynecol. 1994;83:750–754
  27. Bjoro K, Myhre E. The role of chronic non-specific inflammatory lesions of the placenta in intra-uterine growth retardation. Acta Pathol Microbiol Immunol Scand [A]. 1984;92:133–137
  28. Pham T, Steele J, Stayboldt C, et al. Placental mesenchymal dysplasia is associated with high rates of intrauterine growth restriction and fetal demise: a report of 11 new cases and a review of the literature. Am J Clin Pathol. 2006;126:67–78
  29. Svensson AC, Pawitan Y, Cnattingius S, et al. Familial aggregation of small-for-gestational-age births: the importance of fetal genetic effects. Am J Obstet Gynecol. 2006;194:475–479
  30. Stein AD, Ravelli AC, Lumey LH. Famine, third-trimester pregnancy weight gain, and intrauterine growth: the Dutch Famine Birth Cohort Study. Hum Biol. 1995;67:135–150
  31. Kouba S, Hallstrom T, Lindholm C, et al. Pregnancy and neonatal outcomes in women with eating disorders. Obstet Gynecol. 2005;105:255–260
  32. Murphy JF, O’Riordan J, Newcombe RG, et al. Relation of haemoglobin levels in first and second trimesters to outcome of pregnancy. Lancet. 1986;1:992–995
  33. Steer P, Alam MA, Wadsworth J, et al. Relation between maternal haemoglobin concentration and birth weight in different ethnic groups. Br Med J. 1995;310:489–491
  34. Lu ZM, Goldenberg RL, Cliver SP, et al. The relationship between maternal hematocrit and pregnancy outcome. Obstet Gynecol. 1991;77:190–194
  35. Sheiner E, Mazor M, Levy A, et al. Pregnancy outcome of asthmatic patients: a population-based study. J Matern Fetal Neonatal Med. 2005;18:237–240
  36. Jensen GM, Moore LG. The effect of high altitude and other risk factors on birthweight: independent or interactive effects?. Am J Public Health. 1997;87:1003–1007
  37. Galan HL, Rigano S, Radaelli T, et al. Reduction of subcutaneous mass, but not lean mass, in normal fetuses in Denver, Colorado. Am J Obstet Gynecol. 2001;185:839–844
  38. Hammoud AO, Bujold E, Sorokin Y, et al. Smoking in pregnancy revisited: findings from a large population-based study. Am J Obstet Gynecol. 2005;192:1856–1862discussion 1862-1863
  39. Spinillo A, Capuzzo E, Nicola SE, et al. Factors potentiating the smoking-related risk of fetal growth retardation. Br J Obstet Gynaecol. 1994;101:954–958
  40. U.S. Department of Health and Human Services. Women and Smoking: A Report of the Surgeon General. Public Health Service, Office of the Surgeon General; 2001;
  41. Bada HS, Das A, Bauer CR, et al. Low birth weight and preterm births: etiologic fraction attributable to prenatal drug exposure. J Perinatol. 2005;25:631–637
  42. Floyd RL, O’Connor MJ, Sokol RJ, et al. Recognition and prevention of fetal alcohol syndrome. Obstet Gynecol. 2005;106:1059–1064
  43. Bada HS, Das A, Bauer CR, et al. Gestational cocaine exposure and intrauterine growth: maternal lifestyle study. Obstet Gynecol. 2002;100:916–924
  44. Ness RB, Sibai BM. Shared and disparate components of the pathophysiologies of fetal growth restriction and preeclampsia. Am J Obstet Gynecol. 2006;195:40–49
  45. Bernstein PS, Divon MY. Etiologies of fetal growth restriction. Clin Obstet Gynecol. 1997;40:723–729
  46. Villar J, Carroli G, Wojdyla D, et al. Preeclampsia, gestational hypertension and intrauterine growth restriction, related or independent conditions?. Am J Obstet Gynecol. 2006;194:921–931
  47. Abalos E, Duley L, Steyn DW, et al. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database of Systematic Reviews. 2001;CD002252
  48. Stettler RW, Cunningham FG. Natural history of chronic proteinuria complicating pregnancy. Am J Obstet Gynecol. 1992;167:1219–1224
  49. Yasmeen S, Wilkins EE, Field NT, et al. Pregnancy outcomes in women with systemic lupus erythematosus. J Matern Fetal Med. 2001;10:91–96
  50. Rahman P, Gladman DD, Urowitz MB. Clinical predictors of fetal outcome in systemic lupus erythematosus. J Rheumatol. 1998;25:1526–1530
  51. Julkunen H, Jouhikainen T, Kaaja R, et al. Fetal outcome in lupus pregnancy: a retrospective case-control study of 242 pregnancies in 112 patients. Lupus. 1993;2:125–131
  52. Kupferminc MJ, Rimon E, Ascher-Landsberg J, et al. Perinatal outcome in women with severe pregnancy complications and multiple thrombophilias. J Perinat Med. 2004;32:225–227
  53. Kupferminc MJ, Many A, Bar-Am A, et al. Mid-trimester severe intrauterine growth restriction is associated with a high prevalence of thrombophilia. Br J Obstet Gynaecol. 2002;109:1373–1376
  54. Martinelli P, Grandone E, Colaizzo D, et al. Familial thrombophilia and the occurrence of fetal growth restriction. Haematologica. 2001;86:428–431
  55. Howley HE, Walker M, Rodger MA. A systematic review of the association between factor V Leiden or prothrombin gene variant and intrauterine growth restriction. Am J Obstet Gynecol. 2005;192:694–708
  56. Infante-Rivard C, Rivard GE, Yotov WV, et al. Absence of association of thrombophilia polymorphisms with intrauterine growth restriction. N Engl J Med. 2002;347:19–25
  57. Salomon O, Seligsohn U, Steinberg DM, et al. The common prothrombotic factors in nulliparous women do not compromise blood flow in the feto-maternal circulation and are not associated with preeclampsia or intrauterine growth restriction. Am J Obstet Gynecol. 2004;191:2002–2009
  58. Franchi F, Cetin I, Todros T, et al. Intrauterine growth restriction and genetic predisposition to thrombophilia. Haematologica. 2004;89:444–449
  59. Infante-Rivard C, Rivard GE, Guiguet M, et al. Thrombophilic polymorphisms and intrauterine growth restriction. Epidemiology. 2005;16:281–287
  60. Yasuda M, Takakuwa K, Tokunaga A, et al. Prospective studies of the association between anticardiolipin antibody and outcome of pregnancy. Obstet Gynecol. 1995;86:555–559
  61. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med. 2002;346:752–763
  62. Alarcon-Segovia D. Clinical manifestations of the antiphospholipid syndrome. J Rheumatol. 1992;19:1778–1781
  63. Paidas MJ, Ku DH, Arkel YS. Screening and management of inherited thrombophilias in the setting of adverse pregnancy outcome. Clin Perinatol. 2004;31:783–805
  64. Alfirevic Z, Roberts D, Martlew V. How strong is the association between maternal thrombophilia and adverse pregnancy outcome? (A systematic review). Eur J Obstet Gynecol Reprod Biol. 2002;101:6–14
  65. Robertson L, Wu O, Langhorne P, et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol. 2006;132:171–196
  66. Kupferminc MJ, Eldor A, Steinman N, et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med. 1999;340:9–13
  67. Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syndrome: a systematic review. J Am Med Assoc. 2006;295:1050–1057
  68. ACOG Practice Bulletin #68. Antiphospholipid syndrome. Obstet Gynecol. 2005;106:1113–1121
  69. Stella CL, Sibai BM. Thrombophilia and adverse maternal-perinatal outcome. Clin Obstet Gynecol. 2006;49:850–860
  70. Roque H, Paidas MJ, Funai EF, et al. Maternal thrombophilias are not associated with early pregnancy loss. Thromb Haemost. 2004;91:290–295
  71. Rasmussen S, Irgens LM, Albrechtsen S, et al. Predicting preeclampsia in the second pregnancy from low birth weight in the first pregnancy. Obstet Gynecol. 2000;96:696–700
  72. Salihu HM, Sharma PP, Aliyu MH, et al. Is small for gestational age a marker of future fetal survival in utero?. Obstet Gynecol. 2006;107:851–856
  73. Kuno N, Itakura A, Kurauchi O, et al. Decrease in severity of intrauterine growth retardation in subsequent pregnancies. Int J Gynaecol Obstet. 1995;51:219–224
  74. Furuhashi M, Kurauchi O, Suganuma N. Pregnancy following placental abruption. Arch Gynecol Obstet. 2002;267:11–13
  75. Rasmussen S, Albrechtsen S, Dalaker K. Obstetric history and the risk of placenta previa. Acta Obstet Gynecol Scand. 2000;79:502–507
  76. Rasmussen S, Irgens LM, Dalaker K. A history of placental dysfunction and risk of placental abruption. Paediatr Perinat Epidemiol. 1999;13:9–21
  77. Rasmussen S, Irgens LM, Albrechtsen S, et al. Women with a history of placental abruption: when in a subsequent pregnancy should special surveillance for a recurrent placental abruption be initiated?. Acta Obstet Gynecol Scand. 2001;80:708–712
  78. Wallenburg HC, Rotmans N. Prevention of recurrent idiopathic fetal growth retardation by low-dose aspirin and dipyridamole. Am J Obstet Gynecol. 1987;157:1230–1235
  79. Fuke Y, Aono T, Imai S, et al. Clinical significance and treatment of massive intervillous fibrin deposition associated with recurrent fetal growth retardation. Gynecol Obstet Invest. 1994;38:5–9
  80. Cheng CJ, Bommarito K, Noguchi A, et al. Body mass index change between pregnancies and small for gestational age births. Obstet Gynecol. 2004;104:286–292
  81. Olsen SF, Secher NJ, Tabor A, et al. Fish Oil Trials In Pregnancy (FOTIP) Team Randomised clinical trials of fish oil supplementation in high risk pregnancies. Br J Obstet Gynaecol. 2000;107:382–395
  82. Chavez MR, Ananth CV, Smulian JC, et al. Fetal transcerebellar diameter measurement with particular emphasis in the third trimester: a reliable predictor of gestational age. Am J Obstet Gynecol. 2004;191:979–984
  83. Sepulveda W, Rojas I, Robert JA, et al. Prenatal detection of velamentous insertion of the umbilical cord: a prospective color Doppler ultrasound study. Ultrasound Obstet Gynecol. 2003;21:564–569
  84. Nomiyama M, Toyota Y, Kawano H. Antenatal diagnosis of velamentous umbilical cord insertion and vasa previa with color Doppler imaging. Ultrasound Obstet Gynecol. 1998;12:426–429
  85. Nyberg DA, Cyr DR, Mack LA, et al. Sonographic spectrum of placental abruption. AJR Am J Roentgenol. 1987;148:161–164
  86. Chan FY, Pun TC, Lam C, et al. Pregnancy screening by uterine artery Doppler velocimetry: which criterion performs best?. Obstet Gynecol. 1995;85:596–602
  87. Haddad B, Uzan M, Breart G, et al. Uterine Doppler wave form and the prediction of the recurrence of pre-eclampsia and intra-uterine growth retardation in patients treated with low-dose aspirin. Eur J Obstet Gynecol Reprod Biol. 1995;62:179–183
  88. Low-dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy-induced hypertension (Italian study of aspirin in pregnancy). Lancet. 1993;341:396–400
  89. Ebrashy A, Ibrahim M, Marzook A, et al. Usefulness of aspirin therapy in high-risk pregnant women with abnormal uterine artery Doppler ultrasound at 14-16 weeks pregnancy: randomized controlled clinical trial. Croat Med J. 2005;46:826–831
  90. Uzan S, Beaufils M, Breart G, et al. Prevention of fetal growth retardation with low-dose aspirin: findings of the EPREDA trial. Lancet. 1991;337:1427–1431
  91. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol. 1996;174:1584–1589
  92. Rai R, Cohen H, Dave M, et al. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). Br Med J. 1997;314:253–257
  93. Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol. 2002;100:408–413
  94. Empson M, Lassere M, Craig JC, et al. Recurrent pregnancy loss with antiphospholipid antibody: a systematic review of therapeutic trials. Obstet Gynecol. 2002;99:135–144
  95. Chang P, Millar D, Tsang P, et al. Intravenous immunoglobulin in antiphospholipid syndrome and maternal floor infarction when standard treatment fails: a case report. Am J Perinatol. 2006;23:125–129
  96. Gris JC, Mercier E, Quere I, et al. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood. 2004;103:3695–3699
  97. Kupferminc MJ, Fait G, Many A, et al. Low-molecular-weight heparin for the prevention of obstetric complications in women with thrombophilias. Hypertens Pregnancy. 2001;20:35–44
  98. Brenner B, Hoffman R, Blumenfeld Z, et al. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thromb Haemost. 2000;83:693–697
  99. Grandone E, Brancaccio V, Colaizzo D, et al. Preventing adverse obstetric outcomes in women with genetic thrombophilia. Fertil Steril. 2002;78:371–375

PII: S0146-0005(07)00035-3

doi: 10.1053/j.semperi.2007.03.004

Seminars in Perinatology
Volume 31, Issue 3 , Pages 126-134 , June 2007

Article Tools

* Image Usage & Resolution